AUR-AERW-TTP1-B-1-0-R-A741-41
— · D
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- D
- subtype
- D
GSVA pathway preview (0 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR12696758 | — | — | 0.940 |
| 2 | SRR1455060 | GTEX | — | 0.939 |
| 3 | AUR-AFSP-TTP1-A-8-0-R-A741-41 | — | D | 0.933 |
| 4 | BS_4GTESTSE | Ganglioglioma | — | 0.929 |
| 5 | SRR11296796 | — | — | 0.929 |
| 6 | SRR23303775 | — | — | 0.929 |
| 7 | SRR12696768 | — | — | 0.929 |
| 8 | SRR627299 | GTEX | — | 0.924 |
| 9 | SRR12202440 | — | — | 0.923 |
| 10 | SRR934787 | — | — | 0.921 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 3 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| SPERMATOGENESIS | 0.060 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.050 | Remibrutinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.050 | Cobimetinib | — uncovered |